Proteostasis Therapeutics Inc  

(Public, NASDAQ:PTI)   Watch this stock  
Find more results for TSE:PTI
10.50
+0.20 (1.94%)
Dec 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.05 - 10.73
52 week 5.27 - 20.63
Open 10.46
Vol / Avg. 146,748.00/222,931.00
Mkt cap 267.17M
P/E     -
Div/yield     -
EPS -2.30
Shares 24.96M
Beta     -
Inst. own 73%
Nov 10, 2016
Q3 2016 Proteostasis Therapeutics Inc Earnings Release
Oct 27, 2016
Proteostasis Therapeutics Inc Conference Call to Provide Clinical and Scientific Update - Webcast
Sep 29, 2016
Proteostasis Therapeutics Inc at Jefferies Cystic Fibrosis Summit
Sep 28, 2016
Proteostasis Therapeutics Inc at Leerink Partners Rare Disease & IO Roundtable Series - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -628.05% -580.71%
Operating margin -627.93% -568.97%
EBITD margin - -562.66%
Return on average assets -58.17% -164.35%
Return on average equity -71.65% -
Employees 42 -
CDP Score - -

Address

200 Technology Sq Fl 4
CAMBRIDGE, MA 02139-3578
United States - Map
+1-617-2250096 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Proteostasis Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models. Using this platform, it has identified a new class of small molecules, amplifiers that modulate proteins in the proteostasis network. It is developing and intend to commercialize its lead amplifier of CFTR protein, PTI-428, to improve CFTR protein function. It also focuses on developing PTI-NC-733, PTI-130, Usp14 program and unfolded protein response (UPR) program. PTI-130 is a small molecule amplifier.

Officers and directors

M. James Barrett Ph.D. Chairman of the Board
Bio & Compensation  - Reuters
Meenu Chhabra President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
James M. DeTore Chief Financial Officer, Treasurer, Principal Financial Officer
Age: 51
Bio & Compensation  - Reuters
Po-Shun Lee M.D. Executive Vice President, Chief Medical Officer
Bio & Compensation  - Reuters
Brett R. Hagen Principal Accounting Officer, Controller
Age: 43
Bio & Compensation  - Reuters
Janet L. Smart Vice President - Intellectual Property & Legal Affaris
Bio & Compensation  - Reuters